Abstract:Joana Hygino, 1, &ast Marisa C Sales, 2, &ast Priscila M Sacramento, 1 Taissa M Kasahara, 3 Júlio César Costa da Silva, 3 Rafaela Bilhão, 3 Regis M Andrade, 4 Cláudia Cristina Ferreira Vasconcelos, 1 Cleonice AM Bento 1, 3– 5 1 Post-Graduate Program in Neurology, Federal University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil; 2 Post-Graduate Program in Microbiology, University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil; 3 Post-graduate Program in Molecular and Cellular Biology, Federal University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil; 4 Department of General Medicine, Federal University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil; 5 Department of Microbiology and Parasitology, Federal University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil &astThese authors contributed equally to this work Correspondence: Cleonice AM Bento, Department of Microbiology and Parasitology, Federal University of the State of Rio de Janeiro, Frei Caneca 94, 20.261-040, Rio de Janeiro, RJ, Brazil, Tel/Fax + 55-21-2531-7906, Email Purpose: The presence of T cells expressing TLR-2 and TLR-4 has been associated with relapsing-remitting multiple sclerosis (RRMS) pathogenesis. Here, we evaluated whether the effectiveness of DMT in controlling clinical activity of the disease would be associated with modulation of proportion of TLRs + T cells. Patients and Methods: Whole peripheral blood mononuclear cells, purified CD4 + and CD8 + T cells from RRMS patients were cultured with different stimuli. The frequency of IL-17-secreting CD4 + and CD8 + T cells positive for TLR-2 and TLR-4 was determined by flow cytometry. The cytokine profile of these T cells following TLR-2 and TLR-4 stimulation was determined by Multiplex. Some of these T cell cultures were treated with hydrocortisone. The levels of LPS-binding protein (LBP) were dosed by ELISA. Clinical (occurrence of relapses) and radiological (number of active brain lesions) activity were evaluated during the 1-year follow-up. Results: Despite DMT, high intensity of TLR-2 and TLR-4 expression on (CD4 + and CD8 + ) T-cells, as well as the frequency of IL-17-secreting (CD4 + and CD8 + ) T-cells, are predictive of future RRMS relapses. Moreover, higher cytokine production related to Th17/Tc-17 phenotypes in response to TLR-2 and TLR-4 agonists was observed in DMT-treated patients and displayed an elevated number of brain lesions. The hyperresponsiveness of MS-derived T-cells to TLR-2 and TLR-4 ligands, with high levels of IL-1β, IL-6, IL-17, IFN-γ and GM-CSF in response to both TLR agonists, positively correlated with plasma LBP levels. Interestingly, corticoid was less efficient in reducing Th17 and Tc-17 cytokine production induced by TLR-2 and TLR-4 ligands in DMT-treated patients who relapsed during follow-up. Conclusion: Collectively, the data suggested that persistence of circulating Th17 and Tc17 cells expressing elevated levels of functional TLR-2 and TLR-4 could indicate high disease activity and lower therapeutic efficacy in RRMS patients. Keywords: multiple sclerosis, toll-like receptors, T cells, Th17, LPS-binding protein Most patients with multiple sclerosis (MS) suffer from recurrent autoimmune attacks on the myelin sheath of the central nervous system (CNS), coordinated by different cytokines released from effector T-cell subsets, followed by clinical remission. 1 Recurrent acute inflammatory flare-ups can affect any area of the CNS, leading to sensory, autonomic, cognitive, and motor function deficits. 2,3 While acute relapses are commonly treated with corticosteroid, another group of immunomodulatory drugs, named disease-modifying therapies (DMTs), are used to try to reduce the frequency and severity of bouts. 4,5 In RRMS, most frequently prescribed DMT classes mainly targeting memory and activated T cells by different mechanisms. 5,6 Unfortunately, over time, even under DMTs, remission periods become less marked and the majority of relapsing-remitting MS (RRMS) patients progress to a more neurodegenerative form, named secondary progressive MS (SPMS). The risk of disease progression has been mainly observed among RRMS patients with high disease activity, that is characterized by frequent relapses, higher number of brain lesions, and/or deterioration of neurological function during the observation period (1 to 4 years), despite DMT. 7,8 Probably, adverse events that enhance cytokine pro -Abstract Truncated-

Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis

The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study

Hyperresponsiveness of Corticoid-Resistant Th17/Tc-17 Cells to TLR-2 and TLR-4 Ligands is a Feature of Multiple Sclerosis Patients at Higher Risk of Therapy Failure

Relapsing–Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment

Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis

Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials

Impact of treatment on cellular immunophenotype in MS: A cross-sectional study

Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis

Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination

Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

Comparative Efficacy and Safety of Disease-Modifying Therapies in Patients with Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-Analysis

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine

AB0612 Efficacy of Low Dose and Short-Term IL-2 Treatment to Expand Endogenous Regulatory T Cells in Patients with Mixed Connective Tissue Disease

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity

Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.

The frequencies of peripheral blood CD5+CD19+ B cells, CD3−CD16+CD56+ NK, and CD3+CD56+ NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment

Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis

Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis